Columbus, Ohio – September 20, 2026 -- Andelyn Biosciences has begun commercial manufacturing of FAYUVI (rebisufligene etisparvovec-hopf) at its Columbus facility, marking the first FDA-approved gene therapy produced using the company's AAV Curator Platform process. The therapy, developed by Ultragenyx Pharmaceutical Inc., recently received U.S. Food and Drug Administration approval for treating Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA (MPS IIIA).

Taipei – September 19, 2026 -- The 2026 Tang Prize Award Ceremony convened in Taipei on September 18, honoring six laureates across four categories including three scientists whose work led to FDA-approved CAR T-cell cancer therapies now used worldwide.

Madrid – September 19, 2026 -- mAbxience and Sandoz have signed a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar targeting hemophilia A, a treatment referencing Roche's Hemlibra with an estimated global reference market of USD 5.7 billion.

Zurich – September 19, 2026 -- ACROBiosystems has established a dedicated office within The HIVE Innovation Center on Campus Grand Parc in Villejuif, deepening its footprint in France's oncology research corridor. The move, facilitated by real estate operator Kadans Science Partner, gives the roughly 1,000-employee biotechnology group direct proximity to biotechs, hospitals, and translational research institutes clustered around Paris-Saclay.

San Diego – September 19, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) priced $1.3 billion in convertible senior notes due 2033, upsized from an initially announced $1.05 billion offering, carrying a 1.50% annual coupon.

Austin, Texas – – September 19, 2026 -- Otsuka ICU Medical LLC has issued a voluntary user-level recall of one lot of 0.9% Sodium Chloride Injection, USP, 100 mL, after discovering that bags labeled as saline may actually contain highly concentrated Potassium Chloride Injection.

Las Vegas – September 19, 2026 -- The paroxysmal nocturnal hemoglobinuria (PNH) market across the seven major markets was valued at approximately $1.5 billion in 2025 and is projected to grow at a compound annual growth rate of 7.1% through 2036, according to DelveInsight.

South San Francisco, Calif. – September 19, 2026 -- Dualitas Therapeutics has secured a research collaboration and license agreement with Roche worth up to $1 billion, including a $36.5 million upfront payment, to develop bispecific antibody therapeutics for immunology and inflammation diseases.

Shanghai – September 19, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.

London – September 19, 2026 -- Clarivate Plc (NYSE: CLVT) named 22 researchers as its Citation Laureates 2026, identifying scientists whose work the company's Institute for Scientific Information (ISI) considers Nobel-class ahead of this year's Nobel Prize announcements. Since the program began in 2002, 89 previously named Citation Laureates have gone on to win Nobel Prizes.